Join Growin Stock Community!

Staar surgical companySTAA.US Overview

US StockHealthcare
(No presentation for STAA)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

STAA AI Insights

STAA Overall Performance

STAA AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

STAA Recent Performance

-4.62%

Staar surgical company

0.05%

Avg of Sector

-0.31%

S&P500

STAA PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

STAA Key Information

STAA Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

STAA Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone cataract intraocular lenses and injector systems for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.

Price of STAA

STAA FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

STAA Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
178.70
PE Ratio (TTM)
-
Forward PE
72.76
PS Ratio (TTM)
4.26
PB Ratio
2.84
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
82.19%
Net Margin
9.29%
Revenue Growth (YoY)
30136.81%
Profit Growth (YoY)
32462.41%
3-Year Revenue Growth
1039.39%
3-Year Profit Growth
1060.82%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
178.70
PE Ratio (TTM)
-
Forward PE
72.76
PS Ratio (TTM)
4.26
PB Ratio
2.84
Price-to-FCF
-
Gross Margin
82.19%
Net Margin
9.29%
Revenue Growth (YoY)
30136.81%
Profit Growth (YoY)
32462.41%
3-Year Revenue Growth
1039.39%
3-Year Profit Growth
1060.82%

  • When is STAA's latest earnings report released?

    The most recent financial report for Staar surgical company (STAA) covers the period of 2025Q4 and was published on 2025/11/05. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating STAA's short-term business performance and financial health. For the latest updates on STAA's earnings releases, visit this page regularly.

  • Where does STAA fall in the P/E River chart?

    According to historical valuation range analysis, Staar surgical company (STAA)'s current price-to-earnings (P/E) ratio is 0.04, placing it in the Undervalued zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.

  • What is the operating profit of STAA?

    According to the latest financial report, Staar surgical company (STAA) reported an Operating Profit of 18.49B with an Operating Margin of 19.52% this period, representing a growth of 66,348.66% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is STAA's revenue growth?

    In the latest financial report, Staar surgical company (STAA) announced revenue of 94.73B, with a Year-Over-Year growth rate of 193,428.09%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does STAA have?

    At the end of the period, Staar surgical company (STAA) held Total Cash and Cash Equivalents of 176.16M, accounting for 0.39 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does STAA go with three margins increasing?

    In the latest report, Staar surgical company (STAA) achieved the “three margins increasing” benchmark, with a gross margin of 82.21%%, operating margin of 19.52%%, and net margin of 9.38%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess STAA's profit trajectory and future growth potential.

  • Is STAA's EPS continuing to grow?

    According to the past four quarterly reports, Staar surgical company (STAA)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 179.4. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of STAA?

    Staar surgical company (STAA)'s Free Cash Flow (FCF) for the period is 0, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 100% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of STAA?

    The latest valuation data shows Staar surgical company (STAA) has a Price-To-Earnings (PE) ratio of 0.04 and a Price/Earnings-To-Growth (PEG) ratio of 0. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.